From Molecule to Medication: Integrating Menin Inhibitors in AML Practice

Program Description:

Menin inhibitors represent a new treatment approach that targets key leukemia-driving pathways in specific acute myeloid leukemia (AML) subtypes. The role of menin inhibitors in AML requires oncology pharmacists to synthesize complex molecular and clinical data for treatment decisions. Effective management utilizes next-generation sequencing (NGS), European LeukemiaNet (ELN) risk stratification, and measurable residual disease (MRD) assessment, but inconsistent interpretation of genomic reports, prioritization of co-occurring mutations, and variable incorporation of MRD findings hinder this process. Oncology pharmacists often encounter challenges including limited access to mutation-prioritization frameworks, variability in molecular reporting, and rapid therapeutic advancements, and inconsistent guidance and institutional protocols further complicate supportive care implementation. The effective use of oral menin inhibitors requires coordinated workflows for timely therapy initiation. This session will review practical workflows and decision frameworks to integrate menin inhibitors into AML care pathways. Through real-world examples and interactive discussion, oncology pharmacists will explore common access and adherence barriers to oral menin inhibitors, including inpatient stocking challenges, coverage and cost issues, and financial toxicity, along with strategies to leverage patient assistance resources.

Target audience: Oncology Pharmacist

Type of activity: Application

Release date: June 19, 2026

Expiration date: August 19, 2026

Time to complete activity: 1.0 hour

Learner level: Intermediate, Advanced

Fee: Free

Educational Objectives:

At the completion of this activity, participants will be able to:

• Analyze molecular and clinical patient profiles to inform evidence-based selection and sequencing of menin inhibitors within contemporary AML treatment pathways
• Implement risk-adapted monitoring and supportive care strategies to mitigate toxicities associated with menin inhibitor–based AML therapies
• Apply integrated access and workflow strategies to facilitate timely initiation and continuity of oral menin inhibitor therapy across care settings

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number [UAN TBD]. The activity is available for CE credit through August 19, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Kyle Zacholski, PharmD, BCOP, has no relevant financial relationships with ineligible companies to disclose.

Bernard Marini, PharmD, BCOP, FHOPA, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Servier Pharmaceuticals

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:

[email protected]

Privacy Policy and Terms of Use Information:

www.pharmacytimes.org/terms